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OBJECTIVE—Mice with complete deletion of insulin receptor
substrate 2 (IRS2) develop hyperglycemia, impaired hepatic
insulin signaling, and elevated gluconeogenesis, whereas mice
deficient for protein tyrosine phosphatase (PTP)1B display an
opposing hepatic phenotype characterized by increased sensitiv-
ity to insulin. To define the relationship between these two
signaling pathways in the regulation of liver metabolism, we used
genetic and pharmacological approaches to study the effects of
inhibiting PTP1B on hepatic insulin signaling and expression of
gluconeogenic enzymes in IRS2/ mice.
RESEARCH DESIGN AND METHODS—We analyzed glucose
homeostasis and insulin signaling in liver and isolated hepato-
cytes from IRS2/ and IRS2//PTP1B/ mice. Additionally,
hepatic insulin signaling was assessed in control and IRS2/
mice treated with resveratrol, an antioxidant present in red wine.
RESULTS—In livers of hyperglycemic IRS2/ mice, the ex-
pression levels of PTP1B and its association with the insulin
receptor (IR) were increased. The absence of PTP1B in the
double-mutant mice restored hepatic IRS1-mediated phosphati-
dylinositol (PI) 3-kinase/Akt/Foxo1 signaling. Moreover, resvera-
trol treatment of hyperglycemic IRS2/ mice decreased hepatic
PTP1B mRNA and inhibited PTP1B activity, thereby restoring
IRS1-mediated PI 3-kinase/Akt/Foxo1 signaling and peripheral
insulin sensitivity.
CONCLUSIONS—By regulating the phosphorylation state of IR,
PTB1B determines sensitivity to insulin in liver and exerts a
unique role in the interplay between IRS1 and IRS2 in the
modulation of hepatic insulin action. Diabetes 59:588–599,
2010
The insulin receptor substrate (IRS) proteins arekey mediators of insulin and insulin-like growthfactor (IGF)-1 signaling. Of the six IRS proteinsidentified, IRS1 and IRS2 integrate essential sig-
nals from the insulin receptor (IR) and IGF-IR that regu-
late a variety of processes including metabolism and
cellular growth, development, and survival (1). Signaling
by IRS proteins is mediated by two main pathways: the
phosphatidylinositol (PI) 3-kinase and the mitogen-acti-
vated protein kinase pathways. Although IRS1 and IRS2
share similar expression patterns, several lines of evi-
dence suggest the tissue specificity of IRS-mediated sig-
naling in growth and metabolism (2–5). IRS1/ mice
display reduced body size, insulin resistance, and -cell
hyperplasia (2). In contrast, complete deletion of IRS2 in
mice causes defects in hepatic insulin action coincident
with failed suppression of hepatic glucose production
(HGP) (3,5,6) and -cell insufficiency due to impaired
IGF-1 mitogenic signaling (4). Consequently, IRS2-defi-
cient mice develop type 2–like diabetes and most die at
16 week of age as a result of diabetes complications.
Regarding insulin action in the liver, the transcription
factor Foxo1 links IRS/PI-3 kinase-mediated signaling to
the regulation of various genes involved in metabolic
pathways (7). Activation of Akt/Foxo1 phosphorylation in
the response to insulin treatment is disrupted in hepato-
cytes of IRS2/ mice (8). However, recent studies have
demonstrated that Foxo1 phosphorylation in liver may be
effectively mediated by either IRS1 or IRS2 signaling
(9–12).
Protein tyrosine phosphatases (PTPs) catalyze the de-
phosphorylation of tyrosine-phosphorylated proteins (13)
and are negative regulators of tyrosine kinase receptor–
mediated signaling. PTP1B directly interacts with both the
IR and IGF-1R (14,15). The importance of PTP1B in
hepatic metabolism has been demonstrated in vivo and in
cellular models (16,17). Mice lacking the ptpn1 gene
exhibit increased insulin sensitivity owing to enhanced
phosphorylation of IR in liver and skeletal muscle, resis-
tance to weight gain on a high-fat diet, and an increased
basal metabolic rate (18–20). Moreover, the ability of
insulin to suppress HGP is enhanced in PTP1B/ mice.
We have recently demonstrated that sensitivity to insulin
in liver as a result of PTP1B deficiency is acquired during
postnatal development: adult, but not neonatal, PTP1B/
hepatocytes display increased insulin-mediated signaling via
Akt/Foxo1 and a more pronounced inhibition of genes that
regulate gluconeogenesis than in control hepatocytes (21).
Given that the hepatic phenotype of PTP1B/ mice
contrasts with that of IRS2/ mice, we hypothesized that
deletion of PTP1B in this model would restore sensitivity
to insulin. With the present study, we demonstrate that
expression of PTP1B is upregulated in the liver of IRS2/
mice. Moreover, we have observed that the absence of this
phosphatase enables activation of IRS1-mediated Akt/
Foxo1/signaling, thereby restoring hepatic insulin sensitiv-
ity. Thus, genetic ablation of PTP1B or pharmacological
inhibition of its expression and activity by resveratrol
treatment rescues hepatic sensitivity to insulin action in
IRS2/ mice.
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RESEARCH DESIGN AND METHODS
Reagents and antibodies. Fetal serum (FS) and culture media were
obtained from Invitrogen. Insulin for cell culture (I-0516), anti-mouse
immunoglobulin (IgG)-agarose (A-6531), anti–-actin antibody (A-5441),
and resveratrol (R-5010) were from Sigma Aldrich. Protein A-agarose was
from Roche Applied Science. (32P)-ATP (3,000 Ci/mmol), (32P)-dCTP (3,000
Ci/mmol), and a cDNA labeling kit were from GE Healthcare. Anti–phospho-
Foxo1 (Ser 256) (cat. no. 9461), anti–phospho-Akt (Thr 308) (cat. no. 2965),
anti-Akt (cat. no. 9272), anti-phospho-AMP kinase (Thr172) (cat. no. 2531),
and anti-AMP kinase (AMPK) (cat. no. 2532) antibodies were from Cell
Signaling Technology. The anti–phospho-Akt (Ser 473) (sc-7985), anti-IR
-chain for Western blot (sc-711), and anti–phospho-Tyr for immunoprecipi-
tations (Py20, sc-508) antibodies were from Santa Cruz Biotechnology. The
anti-IR -chain antibody (Ab-3; GR07) used for immunoprecipitations was
from Calciochem. The anti-IRS1 (06-248), anti-p85 (06-195), anti-PTP1B
(07-088), anti–acetyl-lysine (clone 4G12; 05-515), and anti–phospho-Tyr (clone
4G10, 05-321) antibodies were obtained from Upstate (Millipore). Anti-SirT1
antibody (Ab12193) was from Abcam. Human regular insulin for animal
experiments (cat. no. 775502; Actrapid) was purchased from Novo Nordisk.
Anti–phosphatidylinositol (PIP)3-fluorescein isothiocyanate (FITC) antibody
(Z-6345) was from Echelon Research Laboratories Inc.
Animals. IRS2/ mice were purchased from The Jackson Laboratories.
PTP1B/ mice were obtained from Abbot Laboratories and have previously
been described (19,21,22). Male IRS2/ and female PTP1B/ mice, main-
tained on a similar mixed genetic background (C57BL/6  129/sv), were
intercrossed to yield IRS2//PTP1B/ mice. The resulting double-heterozy-
gous mice were then intercrossed to obtain all possible genotypes including
double-null IRS2//PTP1B/ mice. Genotyping was performed by PCR as
previously described (23). The various genotypes were born with the expected
Mendelian frequencies. Animals were fed a standard diet ad libitum and had
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FIG. 1. PTP1B deficiency recovers PI 3-kinase/Akt/Foxo1 insulin signaling in the liver of IRS2-deficient mice. A: Wild-type (WT), IRS2/, and
IRS2//PTP1B/ mice (n 9 animals per genotype) were fasted for 4 h, injected intraperitoneally with PBS or human regular insulin (0.75 units/kg),
and killed 15 min later. Livers were removed and total protein extracts were prepared. Then, 600 g total protein were immunoprecipitated with
anti-pTyr antibody and used for an in vitro PI 3-kinase assay. The conversion of PI to PIP3 in the presence of [32-P] ATP was analyzed by thin-layer
chromatography. Total protein (50 g) was analyzed by Western blot with the antibodies against phospho-Akt (Ser 473), phospho-Akt (Thr 308), total
Akt, and phospho-Foxo (Ser 256). A representative experiment is shown from four independent experiments performed. The autoradiograms showing
PI 3-kinase activity were quantitated by scanning densitometry. Results are expressed as fold increase of PI 3-kinase activity and are means  SEM.
*P< 0.05, IRS2//PTP1B/ vs. IRS2/. B: ITT (intraperitoneal injection of 0.75 units/kg human regular insulin) and GTT (intraperitoneal injection
of 2 g D-glucose/kg) tests in wild-type, IRS2/, and IRS2//PTP1B/ mice [n 6–8 per genotype]). Animals were fasted for 4 and 20 h prior to insulin
and glucose tolerance tests, respectively. For ITTs, results are expressed as mean SEM of percentage of initial blood glucose value. For GTTs, results
are expressed as means  SEM of blood glucose value (mg/dl). *P < 0.05, IRS2//PTP1B/ vs. IRS2/.
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FIG. 2. Recovery of insulin signaling and the inhibition of PEPCK and G6Pase in primary hepatocytes from IRS2//PTP1B/ mice. Primary
hepatocytes obtained from mice of each genotype (wild type [WT], IRS2/, and IRS2/PTP1B) were cultured as described in RESEARCH DESIGN AND
METHODS. A: Cells were serum starved for 4–6 h and further stimulated with 10 nmol/l insulin for 5 min. Upper panel: Cells were fixed in methanol
(20°C), and the generation of PIP3 was measured by confocal immunofluorescence with the anti–PIP3-FITC antibody. Representative images
corresponding to primary hepatocytes isolated from one mouse are shown. Lower panel: Cell lysates were prepared, and total protein (50 g)
was used for Western blot analysis with the corresponding antibodies against phospho-Akt (Ser 473), phospho-Foxo (Ser 256), and total Akt. A
representative experiment corresponding to primary hepatocytes isolated from one animal is shown from three independent experiments
performed in triplicate. B: Cells were cultured in serum-free medium for 4–6 h and further stimulated with dex/cAMP (0.5 mmol/l dibutyril cAMP
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free access to drinking water. All animal experimentation was conducted in
accordance with accepted standards of animal care. Trans-resveratrol (25
mg/ml; Sigma) was orally administrated to mice via drinking water in bottles
that were protected from the light, as previously described (24). The dose of
resveratrol is equivalent to 2.5 mg  kg1  day1. During our study, we
confirmed that the mice were in fact consuming the amount of water
necessary to reach the desired pharmacological dose of resveratrol.
Metabolic measurements. For measuring fed and fasted (20- to 24-h fast)
glucose concentrations, blood was obtained from the tail vein and glucose was
assayed using a glucometer (Accu-Check Aviva; Roche). Intraperitoneal
glucose tolerance (GTT) tests were performed on mice fasted for 20–24 h and
injected with 2 g D-glucose/kg body wt, and blood glucose was measured at 30,
60, 90, and 120 min after injection. Intraperitoneal insulin tolerance (ITT) tests
were performed on 4 h–fasted mice injected with 0.75 units/kg human regular
insulin, and blood glucose was measured at 15, 30, 45, and 60 min after
injection.
Insulin signaling studies. Fasted mice were intraperitoneally injected with
PBS or 0.75 units/kg human regular insulin and killed 15 min later. Then, livers
were removed and total protein extracts were prepared as previously de-
scribed (21).
Primary culture of adult hepatocytes. Hepatocytes were isolated from
nonfasting male mice (8–12 weeks old) by perfusion with collagenase as
previously described (25). Cells were plated in 60-mm dishes (Falcon; BD
biosciences) and cultured in William’s Medium E supplemented with 20 ng/ml
epidermal growth factor, 100 units/ml penicillin, 100 g/ml streptomycin, and
10% FS for 48 h. Then, cells were serum starved and used for experiments.
Immunofluorescence and confocal imaging. Cells were grown on glass
coverslips, serum starved for 4–6 h, and stimulated with insulin for 5 min.
Then, cells were washed twice with PBS, fixed in methanol (20°C) for 2 min,
and processed for immunofluorescence. Anti–PIP3-FIIC antibody was applied
for 1 h at 37°C in PBS-1% BSA, followed by four washes of 5 min each in PBS.
Immunofluorescence was examined in an MRC-1024 confocal microscope
adapted to an inverted Nikon Eclipse TE 300 microscope. Immunofluores-
cence mounting medium was from Vector Laboratories.
PI 3-kinase activity, RNA extraction from primary hepatocytes, and
Northern blot analysis. PI 3-kinase activity was measured in the immuno-
precipitates by in vitro phosphorylation of PI as previously described (8).
Total RNA was isolated from primary hepatocytes with Trizol (Invitrogen) and
submitted to Northern blot analysis. Blots were hybridized with cDNA probes
for PEPCK and glucose-6-phosphatase (G6Pase). Membranes were subjected
to autoradiography, and relative quantification of the hybridization signals
was performed by densitometric scanning of the autoradiograms.
Quantitative real-time PCR analysis. Total RNA was isolated from livers
with Trizol reagent (Invitrogen). DNase I–treated RNA was reverse tran-
scribed into cDNA before the PCR assay was performed for ptpn1 gene
expression. Primer-probe sets for murine PTP1B were purchased as prede-
signed TaqMan gene expression assays and run per the manufacturer’s
instructions (Applied Biosystems). The results are given as percentage over
control (wild-type mice or IRS2/ mice treated with resveratrol) after
normalization of mRNA to 18S rRNA expression.
PTP1B phosphatase activity, islet isolation, islet morphology, and
-cell mass. Livers were homogenized in buffer containing 20 mmol/l
imidazole HCl, 2 mmol/l EGTA, and 2 mmol/l EDTA (pH 7.0) supplemented
with protease inhibitors (10 mg/ml leupeptin, 10 mg/ml aprotinin, and 1 mmol/l
phenylmethylsulfonyl fluoride). Cell lysates were applied through a Sephadex
G-25 column to remove the free phosphate. After protein content determination,
PTP1B phosphatase activity was determined by measuring phosphate release
using a synthetic monophosphotyrosyl-containing peptide and the malachite
green assay (cat. no. 17-125; Millipore). The protocols for islet isolation, analysis
of islet morphology, and -cell mass have previously been described (26).
PTP1B immunohistochemistry in islets. Pancreata from 8- to 12-week-old
mice were fixed with 4% paraformaldehyde overnight and cryoprotected in
PBS containing 30% sucrose. Cryostat sections (10 m) were cut and kept at
80°C until used. Sections were brought to room temperature, permeabilized
with methanol for 2 min (20°C), treated with 10% normal goat serum, and
then incubated overnight with the anti-PTP1B antibody (1:50 dilution, sc-
14021; Santa Cruz Biotechnology) overnight at 4°C. Immunodetection was
carried out with a secondary biotinylated goat anti-rabbit antiserum using
3-3	diaminobencidine (Vector). Sections were examined in a Nikon Eclipse
90i microscope, and light microphotographs were taken with an associated
Leitz digital camera (Leitz DFC300 FXC).
Statistical analysis. The data are expressed as means 
 SD. The statistical
significance was estimated with Student’s t test for unpaired observation. The
results were considered significant at P  0.05.
RESULTS
PTP1B deficiency restores insulin-activated PI 3-ki-
nase/Akt/Foxo1 signaling in the liver of IRS2-defi-
cient mice. IRS2-deficient mice display hepatic insulin
resistance and -cell failure (3,5). Previous results pub-
lished by Withers et al. (3) have demonstrated that insulin-
stimulated IRS1-associated PI 3-kinase activity is significantly
reduced in liver of IRS2/ mice. Conversely, PTP1B-
deficient mice are characterized by hypersensitivity to
insulin in the activation of hepatic PI 3-kinase associated
with IRS1/2 (18,20). Based on these observations, we
postulated that enhanced insulin signaling in the liver as
promoted by PTP1B deficiency would compensate for the
lack of IRS2 and thereby restore insulin action in hepato-
cytes. As shown in Fig. 1A, total (anti–pTyr associated)
PI-3 kinase activity was activated by insulin in liver from
wild-type mice, whereas this response to insulin was
absent in 12- to 16-week-old hyperglycemic (fasting blood
glucose 300 mg/dl) IRS2/ mice. However, insulin-
stimulated PI-3 kinase activity was completely restored in
the liver of IRS2//PTP1B/ mice of the same age.
Downstream of PI 3-kinase, the phosphorylation of Akt at
the catalytic (Thr 308) and hydrophobic (Ser 473) sites
was reduced in the liver of hyperglycemic IRS2/ mice
but was also rescued by the absence of PTB1B in double-
mutant mice (Fig. 1A). Consistent with this, insulin failed
to induce the phosphorylation of Foxo1 in the absence of
IRS2, but this response was normal in liver of IRS2//
PTP1B/ mice. Collectively, these results indicate that
the defective PI 3-kinase/Akt/Foxo1 signaling in the liver
of hyperglycemic IRS2/ mice can be completely re-
versed by the absence of PTP1B expression. In agreement
with the data reported by Kushner et al. (23), PTP1B
deficiency normalized fasting blood glucose (wild type
63 
 2.35 mg/100 ml, IRS2/ 169 
 19.15 mg/100 ml, and
IRS2//PTP1B/ 111 
 4.37 mg/100 ml), fed blood
glucose (wild type 138.81 
 2.6 mg/100 ml, IRS2/
426.8
 35.7 mg/100 ml, and IRS2//PTP1B/ 129.6
 3.5
mg/100 ml), peripheral insulin sensitivity, and glucose
tolerance in IRS2//PTP1B/ mice (Fig. 1B).
Restoration of insulin-mediated inhibition of PEPCK
and G6Pase in primary hepatocytes from IRS2//
PTP1B/ mice. We have previously shown that in pri-
mary hepatocytes lacking IRS2, insulin failed to activate PI
3-kinase–mediated signaling, which inhibits expression of
the gluconeogenic enzymes PEPCK and G6Pase (8). Thus,
we investigated the effect of PTP1B deficiency on insulin-
stimulated signaling in IRS2/ hepatocytes. Consistent
with observations in vivo, insulin failed to increase PIP3
levels or to induce the phosphorylation of Akt/Foxo1 in
hepatocytes prepared from 12- to 16-week-old hyperglyce-
mic IRS2/ mice compared with wild-type controls. How-
ever, in primary hepatocytes lacking both IRS2 and
PTP1B, insulin promoted PIP3 formation and Akt/Foxo1
phosphorylation at levels comparable with those in wild-
type hepatocytes (Fig. 2A).
plus 1 mol/l dexamethasone) in the absence or presence of insulin (10 or 100 nmol/l) for 6 h. At the end of the culture time, RNA was isolated
and submitted to Northern blot analysis. A representative experiment corresponding to primary hepatocytes isolated from one mouse is shown.
The autoradiograms corresponding to three independent experiments performed in hepatocytes were quantitated by scanning densitometry. The
value of dex/cAMP-treated cells was set to 100%. Results are expressed as percentage of decrease by insulin of PEPCK and G6Pase mRNAs and
are means  SEM. *P < 0.05, IRS2//PTP1B/ vs. IRS2/. (A high-quality digital representation of this figure is available in the online issue.)
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In vivo resistance to insulin in the livers of IRS2/ mice
is manifest by the failure of the hormone to suppress HGP
(3). Thus, we investigated the ability of insulin to inhibit
transcription of the genes for PEPCK and G6Pase in
primary hepatocytes from wild-type, hyperglycemic
IRS2/ and IRS2//PTP1B/ mice. As shown in Fig. 2B,
the mRNA levels for both PEPCK and G6Pase were
upregulated by dexamethasone and cAMP in all genotypes
regardless of IRS2 expression. However, insulin (10
nmol/l) failed to downregulate PEPCK and G6Pase mRNAs
in IRS2-deficient hepatocytes. Of note, a higher dose of
insulin (100 nmol/l) was able to suppress gluconeogenic
gene expression in IRS2/ hepatocytes, confirming the
presence of severe insulin resistance. The inhibitory effect
of insulin on PEPCK and G6Pase mRNAs was restored in
hepatocytes from IRS2//PTP1B/ mice.
Both PTP1B expression and enzymatic activity are
upregulated in the livers and islets of hyperglycemic
IRS2/ mice. Since IR/IRS2-mediated insulin signaling is
essential for maintaining glucose homeostasis, we exam-
ined the expression of key molecules that regulate the
early steps of the insulin-signaling cascade in the livers of
wild-type, hyperglycemic IRS2/ and normoglycaemic
IRS2//PTP1B/ mice. The expression of IR, IRS1, and
β-actin
β-actin
  
PTP1B  
PTEN  
p85α 
IRS-1  
IRβ  
PT
P1
B
 e
xp
re
ss
io
n
(fo
ld
 in
cr
ea
se
)  
 
PT
P1
B
/1
8S
(a
rb
itr
ar
y 
un
its
)  
 
PT
P1
B
 a
ct
iv
ity
(p
m
ol
/m
in
/µ
g 
pr
ot
)  
 
WT
3
2
1
0
A 
B C 
* 
* * 
SHP-2  
WT 
  
PTP1B   
WT 
0,5
0,4
0,3
0,2
0,1
0
1,5
1
0,5
0
WT WT 
Primary hepatocytes
IRS-2-/-
IRS-2-/- IRS-2-/-
PTP1B-/-
IRS-2-/- IRS-2-/-
PTP1B-/-
IRS-2-/- IRS-2-/-
PTP1B-/-
IRS-2-/- IRS-2-/-
PTP1B-/-
FIG. 3. Both PTP1B expression and its enzymatic activity were upregulated in the livers of IRS2/ mice. A (upper panel): Liver extracts from
wild-type (WT), IRS2/, and IRS2//PTP1B/ mice (n 9 of each genotype) were prepared and total protein (50 g) was used for Western blot
analysis with the corresponding antibodies against insulin-signaling molecules. The anti–-actin antibody was used as a loading control. A
representative experiment is shown. The autoradiograms showing PTP1B from all animals analyzed were quantitated by scanning densitometry.
Results are expressed as fold increase of PTP1B content and are means  SEM. *P < 0.05, IRS2/ vs. wild type. Lower panel: Primary
hepatocytes obtained from mice of each genotype (wild type, IRS2/, and IRS2//PTP1B/) were cultured as described in RESEARCH DESIGN AND
METHODS. Cell lysates were prepared and total protein (50 g) was used for Western blot analysis with the corresponding antibodies against
PTP1B. A representative experiment corresponding to primary hepatocytes isolated from one animal is shown from three independent
experiments performed in triplicate. B: Total RNA was isolated from livers of wild-type and IRS2/ mice (n  9 of each genotype). PTP1B mRNA
levels were determined by real-time PCR. Results are expressed as arbitrary units of PTP1B/18S mRNA and are means  SEM. *P < 0.05, IRS2/
vs. wild type. mRNA from IRS2//PTP1B/ mice was used as a negative control. C: PTP1B activity was measured in wild-type and IRS2/ liver
extracts (n  5 of each genotype) as described in RESEARCH DESIGN AND METHODS. Results are expressed as pmol  min1  g protein1 and are
means  SEM. PTP1B activity from IRS2//PTP1B/ liver extracts was used as a negative control. *P < 0.05, IRS2/ vs. wild type.
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p85 was equivalent between the three groups of mice
(Fig. 3A). However, the levels of PTP1B protein and mRNA
were significantly upregulated in the livers of hyperglyce-
mic IRS2/ mice compared with controls (Fig. 3A and B).
PTP1B protein levels were also enhanced in primary
hepatocytes prepared from hyperglycemic IRS2/ mice
(Fig. 3A). Importantly, PTP1B activity was also increased
in liver extracts from hyperglycemic IRS2/ mice com-
pared with wild-type mice (Fig. 3C). Hepatic expression of
the tyrosine phosphatase small heterdimer partner (SHP2)
and the PIP3 inositol phosphatase PTEN was similar
among the three genotypes of mice (Fig. 3A). As IRS2/
mice also present abnormalities in -cell growth that are
partly reversed by PTP1B deletion (23), we investigated
whether the expression of this phosphatase was also
elevated in IRS2/ pancreatic islets. Indeed, PTP1B
mRNA levels were higher in islets from hyperglycemic
IRS2/ mice compared with those isolated from control
mice (Fig. 4A). Moreover, immunohistochemistry analysis
revealed more PTP1B staining in IRS2/ islets than in
wild-type controls (Fig. 4B).
The lack of PTP1B in hyperglycemic IRS2/ mice
restores hepatic IRS1-mediated PI 3-kinase signaling
by releasing IR/PTP1B association. The fact that insu-
lin-mediated PI 3-kinase/Akt/Foxo1 signaling was impaired
in the livers of hyperglycemic IRS2/ mice, along with the
elevated expression and activity of PTP1B, prompted us to
determine whether IRS1-mediated PI 3-kinase signaling
was restored in IRS2//PTP1B/ mice. Whereas insulin-
induced IRS1 tyrosine phosphorylation and PI 3-kinase
activity were blunted in the liver of hyperglycemic IRS2/
mice, these responses were completely restored in IRS2//
PTP1B/ mice (Fig. 5A). Upstream of IRS1 activation,
insulin-mediated tyrosine phosphorylation of IR was com-
pletely absent in the liver of hyperglycemic IRS2/ mice
but was also rescued in IRS2//PTP1B/ mice. Consis-
tent with this, the basal association of PTB1B with IR was
significantly augmented in liver extracts from hyperglyce-
mic IRS2/ mice compared with the wild-type controls
(Fig. 5B). However, we did not observe that IRS2 defi-
ciency altered the PTP1B/IRS1 association. Thus, these
results demonstrate that the absence of IRS2 leads to
increased expression of PTP1B in the liver and enhanced
association of this phosphatase with IR, thereby blocking
IR/IRS1-mediated insulin signaling.
Treatment of hyperglycemic IRS2/ mice with res-
veratrol downregulates PTP1B in the liver and pro-
motes insulin-induced IRS1/Akt/Foxo1 signaling. We
next investigated whether insulin sensitivity in the liver of
hyperglycemic IRS2/ mice could be restored by phar-
macologically targeting PTP1B. Resveratrol, a plant-de-
rived polyphenol that is a potent activator of SIRT1, has
been reported to repress PTP1B expression in the liver
under high-fat diet–induced insulin resistance (24). Thus,
hyperglycemic IRS2/ mice were treated with resveratrol
(2.5 mg  kg1  day1) for 8 weeks and hepatic insulin
signaling was analyzed. As shown in Fig. 6A, both insulin-
induced IRS1-associated PI 3-kinase activity and Akt/
Foxo1 phosphorylation were significantly increased in
resveratrol-treated IRS2/ mice compared with untreated
IRS2-deficient mice. Of note, treatment with resveratrol
did not alter IRS1 acetylation in the livers of IRS2/ mice.
Consistent with the restoration of insulin sensitivity, res-
veratrol therapy decreased PTP1B mRNA, protein levels,
and phosphatase activity in the livers of IRS2/ mice
compared with untreated mice (Fig. 6A–C). Conversely,
neither SirT1 levels nor the phosphorylation of its down-
stream effector AMPK (27) was affected by resveratrol
treatment (Fig. 6A). Moreover, resveratrol improved sys-
temic insulin sensitivity in IRS2/ mice but did not
change glucose tolerance (Fig. 6D). Blood glucose re-
mained elevated in both the fasted (IRS2/ 169.0 
 19.15
mg/100 ml; IRS2/, resveratrol 169.77 
 17.80 mg/100 ml)
and fed (IRS2/ 426.80 
 35.70 mg/100 ml; IRS2/,
resveratrol 448.9 
 40 mg/100 ml) states compared with
control untreated mice. Consistent with this, resveratrol
treatment of IRS2/ mice did not improve islet morphol-
ogy or -cell mass compared with untreated mice (results
not shown).
To further confirm these data, we prepared primary
hepatocytes from IRS2/ mice that had been treated with
resveratrol, and PTP1B levels and insulin signaling were
analyzed. Figure 7A reveals that PTP1B was downregu-
lated and insulin strongly induced the phosphorylation
of Akt/Foxo1 in hepatocytes from resveratrol-treated
IRS2/ mice compared with primary hepatocytes from
untreated hyperglycemic IRS2/ mice. Additionally, the
ability of insulin to inhibit PEPCK and G6Pase mRNAs was
restored in hepatocytes from resveratrol-treated IRS2/
mice (Fig. 7B). These results demonstrate that resveratrol,
by inhibiting the expression/activity of PTB1B, promotes
insulin sensitivity in IRS2/ hepatocytes. To substantiate
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these data, we treated primary hepatocytes from IRS2/
mice with 50 mol/l resveratrol for 24 h and then stimu-
lated with insulin. As shown in Fig. 7C, resveratrol treat-
ment downregulated PTP1B in IRS2/ hepatocytes and,
therefore, insulin-induced Akt and Foxo1 phosphorylation
were restored.
DISCUSSION
IRS proteins coordinate signaling pathways that regulate
metabolism and cell growth and survival. Understanding
the molecular regulation of IRSs is crucial for identifying
new targets to treat or prevent insulin resistance and
metabolic diseases. The IRS2 knockout mouse is a genetic
model with defective PI 3-kinase/Akt/Foxo1–mediated in-
sulin signaling in the liver, which causes increased HGP
(3). Since inhibition of PTP1B has been demonstrated to
enhance PI 3-kinase signaling in the liver (18,20), the
present study has investigated whether elimination or
reduction of PTP1B expression by genetic or pharmaco-
logical approaches could restore hepatic sensitivity to
insulin in IRS2/ mice that displayed fasting hyperglyce-
mia (300 mg/dl) at 12–16 weeks of age.
Foxo1 has been established as the molecular link between
Akt phosphorylation and gluconeogenic gene expression
(28,29). However, we observed that in insulin-treated
IRS2/ hepatocytes, Foxo1 remained unphosphorylated
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and the expression of PEPCK and G6Pase was elevated.
These results are consistent with previous data (3) dem-
onstrating that the ability of IRS1 to activate PI 3-kinase in
response to insulin was severely impaired in the liver of
IRS2/ mice. Interestingly, our current results reveal that
the inability of insulin to phosphorylate Foxo1 through
activation of PIP3/Akt in the liver of IRS2/ mice can be
reversed by PTP1B deletion. This is a critical finding
because both IRS1 and IRS2 can efficiently activate the PI
3-kinase pathway in the liver to mediate the physiological
responses to insulin in regulating carbohydrate and lipid
metabolism, as has been demonstrated recently in mice
with liver-specific deletions of both IRS1 and IRS2 (9–12).
Importantly, our results demonstrate that mRNA, protein
levels, and the phosphatase activity of PTP1B were ele-
vated in the livers of systemic IRS2/ mice compared
with wild-type controls. However, genetic deletion or
pharmacological inhibition (see below) of PTP1B com-
pletely restored IRS1-mediated PI 3-kinase/Akt/Foxo1 sig-
naling and insulin-mediated inhibition of gluconeogenic
gene expression in the liver of IRS2/ mice. Thus, our
results show for the first time that the impairment of
IRS1-mediated signaling in the liver of IRS2/ mice can
be fully corrected by the lack of PTP1B. Moreover, these
findings suggest that the upregulation of PTP1B expres-
sion and phosphatase activity represents the molecular
mechanism underlying the loss of sensitivity to insulin in
liver of hyperglycemic IRS2/ mice. IR is a major sub-
strate for PTP1B (14), and our results further demonstrate
that upregulation of PTB1B in liver of IRS2/ mice
enhances the IR/PTP1B association. Consequently, the
increased dephosphorylation of IR is likely to be respon-
sible for the inability of IRS1 to mediate insulin signaling in
the liver of IRS2/ mice. Thus, the absence of PTP1B in
the double-mutant mice promotes insulin sensitivity in the
liver by enabling the activation of an IR/IRS1-mediated
compensatory mechanism, culminating in the inhibition of
PEPCK and G6Pase in hepatocytes.
When the physiological consequences resulting from the
complete deletion of IRS2 are compared with liver-specific
conditional knockouts of IRS2, it is intriguing that IRS1 is
able to compensate for the lack of IRS2 signals in the
liver-specific models (9–12) but not in the total body (3) of
IRS2/ mice. Complete disruption of IRS2 causes hyper-
glycemia at 10–12 weeks of age (3,5), whereas hypergly-
cemia was not reported in liver-specific IRS2/ mice
(9–12). IRS2 deficiency impairs development and expan-
sion of pancreatic -cells owing to the lack of IGF-I
signaling (4), thereby precluding -cell hyperplasia as a
compensatory response in the whole-body knockout
model. However, this is not the case for liver-specific
deletions of IRS2 where the compensatory mechanisms
employed by -cells remain intact. Interestingly, it has
been demonstrated recently that high glucose enhances
PTP1B transcription in human hepatocytes (30). There-
fore, the presence of hyperglycemia might explain the
increased levels of PTP1B mRNA and protein detected in
the livers and islets of the IRS2/ mice by the present
study. Given that complete deletion of IRS2 causes multi-
ple metabolic defects, other systemic components such as
defective -cell function, hyperleptinemia, or dyslipidemia
may also modulate hepatic PTB1B expression. Mice het-
erozygous for both IR and IRS1 (DHet mice) display severe
insulin resistance and hyperglycemia (250 mg/dl); dele-
tion of PTB1B in this model restored hepatic IRS1/IRS2-
associated PI 3-kinase activity in response to insulin and
markedly improved glucose tolerance and insulin sensitiv-
ity (31). However, no data were reported regarding PTP1B
levels or activity in the liver of DHet mice.
It has recently been shown that the antioxidant resvera-
trol improves insulin sensitivity in insulin-resistant livers
by repressing PTP1B (24). Our present findings clearly
demonstrate that resveratrol exerts a protective effect
against hepatic insulin resistance in IRS2/ mice by
reducing both PTP1B expression and phosphatase activ-
ity. This result is particularly interesting because AMPK
phosphorylation, a downstream target of SirT1 (27), was
not altered by resveratrol treatment of IRS2/ mice. The
ability of insulin to stimulate IRS1-mediated PI 3-kinase
signaling was restored to normal in IRS2-deficient mice
treated with resveratrol. Thus, hepatocytes from resvera-
trol-treated IRS2/ mice responded to insulin by inhibit-
ing PEPCK and G6Pase. These data are consistent with
those obtained by the genetic ablation of PTB1B in the
IRS2-deficient model and suggest that resveratrol might be
employed to treat hepatic insulin resistance. However, the
inability of resveratrol to improve glucose tolerance in
IRS2/ mice indicates that treatment with this polyphe-
nol does not reverse the severe defects in -cell prolifer-
ation and survival that are due to impaired IGF-1 signaling
(4). The observed failure of resveratrol to improve the
pancreatic phenotype of IRS2/ mice was most likely due
to the fact that this compound was administered to
animals upon weaning when islet damage was already
present, making it difficult to overcome the developmental
reduction of -cell mass and the loss of existing islets
during the pre-diabetic and diabetic phases in mice lacking
IRS2. Although the present study validates PTP1B as an
attractive target for treatment of hepatic insulin–resistant
states in humans, pharmacological therapies based on this
phosphatase must be developed carefully given the pleio-
tropic effects of PTP1B on receptor tyrosine kinase signal-
ing. In this regard, PTP1B-deficient liver cells are
protected against apoptosis and liver failure (32,33). Re-
cent studies have demonstrated that inhibition of PTP1B
has beneficial effects on breast and colon tumorigenesis
(34–36), suggesting that the use of PTP1B inhibitors for
the treatment of hepatic insulin resistance might also
protect against cancer.
In conclusion, our results demonstrate that elevated
expression and activity of PTP1B in the liver of hypergly-
cemic IRS2/ mice impair IR/IRS1-mediated insulin sig-
naling by increasing the association of IR with this
phosphatase. Accordingly, deletion of PTP1B promotes
insulin sensitivity in the liver of IRS2/ mice through the
restoration of IRS1-mediated Akt/Foxo1 phosphorylation
and the inhibition of gluconeogenic enzymes. This molec-
ular mechanism (summarized in Fig. 8) can be mimicked
by resveratrol through downregulation of PTP1B activity
in liver of IRS2/ mice. Thus, PTP1B has a unique role in
densitometry. The value of dex/cAMP-treated cells was set to 100%. Results are expressed as percentage of decrease by insulin of PEPCK and
G6Pase mRNAs and are means  SEM. *P < 0.05, treated vs. untreated. C: Primary hepatocytes obtained from IRS2/ mice were cultured as
described in RESEARCH DESIGN AND METHODS. Cells were treated with 50 mol/l resveratrol for 24 h, serum-starved for 2 h, and then stimulated with
10 nmol/l insulin for 5 min. After cell lysates were prepared, total protein (50 g) was used for Western blot analysis with the corresponding
antibodies against phospho-Akt (Ser 473), phospho-Foxo (Ser 256), total Akt, and PTP1B. A representative experiment corresponding to primary
hepatocytes isolated from one animal is shown from three independent experiments performed in triplicate.
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modulating the signaling of IRS1 and IRS2 in the regulation
of hepatic metabolic pathways and represents a rational
target for the development of new pharmacological agents
aimed at improving hepatic insulin sensitivity.
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